TriAxis Biosciences
Prototype · Validation Phase

The TriAxis Platform

A wastewater-based metagenomic surveillance platform — designed to detect community-level antimicrobial resistance signals weeks ahead of clinical reporting.

Our platform reads the full microbial and resistance gene content of community wastewater. Where targeted surveillance methods only find what they’re already looking for, our approach goes further — surfacing known AMR markers, emerging variants, and novel resistance signals from the same sample.

The output: actionable early-warning intelligence, designed for the agencies that act on it.

End-to-end approach

Sample

Routine wastewater collection

Sequence

Metagenomic sequencing

Signal

Bioinformatic resistance intelligence

Labeled river water sample bottles at collection site

River water sample

Labeled effluent sample bottles at treatment facility

Effluent sample

What the platform does — and where we are in building it.

01

What It Detects

The full antimicrobial resistance gene landscape circulating in a community — known markers, emerging variants, and previously uncatalogued signals. Because metagenomics reads the full sample, the data already contains tomorrow's threats; we just have to learn to read them.

02

How It Works

From sample to signal. Community wastewater moves through a standardized computational process that turns raw sequence into resistance trend signals. (We keep the detailed method confidential ahead of publication.)

03

Where We Are

Currently in prototype, validating against published clinical AMR datasets. The validation work is the prerequisite for everything that follows — no field claims, no pilot deployments, no public dashboards until the bioinformatic engine has earned them in the data.

Next

How do we know it works?

See the validation approach →